title: Adult liver transplantation: the Paul Brousse experience.
abstract: During the past 3 decades, more than 2,250 liver transplants were performed at Paul Brousse Hospital. Overall patient survival was 82% at one year, 71% at 5 years and 64% at 10 years. Our group has developed a variety of approaches to liver transplantation, including: 1. Anti HBs immunoglobulin prophylaxis for the prevention of HBV recurrence. Combination prophylaxis with lamivudine and anti HBs immunoglobulins reduced the rate of HBV re-infection to 20%. 2. Transplantation of HIV-HCV and HIV-HBV infected patients. These transplants are feasible and we achieved 2- year survival rates of 70% and 90%, respectively. The main problem was HCV recurrence which was more severe in HIV co-infected patients. 3. Transplantation for hepatocellular carcinoma on a cirrhotic liver with a single tumor <5 cm or <3 tumors <3 cm. 4. Transplantation for familial amyloidotic polyneuropathy (FAP). The 5- and 10-year survival rates were 76% and 72%, respectively. More than 100 livers obtained after hepatectomy from FAP patients were transplanted as "domino" living donor livers to patients with unresectable liver cancers with a 5-year survival rate of 64%. In some domino recipients, symptoms of FAP disease occurred more rapidly than expected and this could be an indication for a second transplantation of a non FAP-liver. 5. Split-liver transplantation for pediatric patients. This has increased the number of transplantable livers for children by 28%. 6. Split-liver transplantation for 2 adults. The grafts were prepared by ex-vivo or in-situ splitting and the overall 5-year survival rate was 56%. 7. Adult -to-adult living-related liver transplantation. There has been no mortality nor late complications in donors and the overall 5-year survival rate among recipients was 73%. 8. Liver retransplantation with good results in the elective situation. Retransplantation should be used with discretion in the emergency setting.
authors.affiliation: AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Université Paris-Sud.
authors.forename: D
authors.initials: D
authors.lastname: Castaing
authors.forename: C
authors.initials: C
authors.lastname: Salloum
authors.forename: D
authors.initials: D
authors.lastname: Azoulay
authors.forename: R
authors.initials: R
authors.lastname: Adam
authors.forename: E
authors.initials: E
authors.lastname: Vibert
authors.forename: L A
authors.initials: LA
authors.lastname: Veilhan
authors.forename: V
authors.initials: V
authors.lastname: Karam
authors.forename: F
authors.initials: F
authors.lastname: Saliba
authors.forename: Ph
authors.initials: P
authors.lastname: Ichaï
authors.forename: D
authors.initials: D
authors.lastname: Samuel
mesh_terms: D000328:Adult; D006085:Graft Survival; D006801:Humans; D017093:Liver Failure / Q000401:mortality* / Q000601:surgery*; D016031:Liver Transplantation / Q000379:methods / Q000401:mortality*; D014019:Tissue Donors / Q000706:statistics & numerical data / Q000600:supply & distribution